Portola, Daiichi Sankyo deal

The companies agreed to expand to Germany the ongoing open-label, international Phase IIIb/IV ANNEXA-4 trial evaluating Portola's AndexXa andexanet alfa as an antidote for Lixiana edoxaban, Daiichi’s oral Factor Xa inhibitor. Portola, which is sponsoring the trial, will receive $15 million up front and is eligible for up to $10 million in clinical milestones. Daiichi is eligible for low single-digit royalties capped at $8 million on AndexXa sales. Portola expects to open the first German sites "in the next few months." Daiichi did not respond to inquiries...